Therapeutic intervention and targets for sepsis

Annual Review of Medicine

Volumn 56, Issue , 2005, Pages 225-248

  Rice, Todd W ^a   Bernard, Gordon R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drotrecogin alfa (activated); Heparin; HMGB 1; Hydrocortisone; Tissue factor pathway inhibitor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLCYSTEINE; ANTISERUM; ANTITHROMBIN III; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BRADYKININ ANTAGONIST; CORTICOSTEROID; DROTRECOGIN; HYBRID PROTEIN; IBUPROFEN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LIPID A; METHYLENE BLUE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; PENTOXIFYLLINE; PROSTAGLANDIN E1; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SELENIUM; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

BLOOD CLOTTING; CLINICAL FEATURE; CLINICAL TRIAL; HEMOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INTENSIVE CARE; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEPSIS; SYSTEMATIC REVIEW;

ADRENAL CORTEX HORMONES; ANTITOXINS; BLOOD COAGULATION; CARDIOPULMONARY RESUSCITATION; CRITICAL CARE; ENDOTOXINS; HMGB PROTEINS; HUMANS; INFLAMMATION MEDIATORS; LIPOPROTEINS; MONITORING, PHYSIOLOGIC; PROTEIN C; RECOMBINANT PROTEINS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 14544299688     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.082103.104356     Document Type: Review

References (122)

1. Bone RC, Balk RA, Cerra FB, et al. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644-55
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-10
3. Martin GS, Mannino DM, Eaton S, et al. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-54
4. Weycker D, Akhras KS, Edelsberg J, et al. 2003. Long-term mortality and medical care charges in patients with severe sepsis. Crit. Care Med. 31:2316-23
5. Quartin AA, Schein RM, Kett DH, et al. 1997. Magnitude and duration of the effect of sepsis on survival. JAMA 277:1058-63
6. Zeni F, Freeman B, Natanson C. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment (editorial). Crit. Care Med. 25:1095-100
7. Rangel-Frausto MS, Pittet D, Costigan M, et al. 1995. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 273:117-23
8. van der Poll T, van Deventer SJH. 1999. Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. N. Am. 13:413-26
9. van der Poll T. 2001. Immunotherapy of sepsis. Lancet Infect. Dis. 1:165-74
10. Thijs LG, Hack CE. 1995. Time course of cytokine levels in sepsis. Intensive Care Med. 21(Suppl. 2):S258 (Abstr.)
11. van Deventer SJH, Buller HR, ten Cate JW, et al. 1990. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76:2520-26
12. Matthay MA. 2001. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N. Engl. J. Med. 344:759-62
13. Marik PE, Varon J. 2003. Sepsis. In Irwin and Rippe's Intensive Care Medicine, ed. RS Irwin, JM Rippe, 5:1822-33. Philadelphia: Lippincott, Williams & Wilkins. 2367 pp.
14. Curfs JH, Meis JF, Hoogkamp-Korstanje JA. 1997. A primer on cytokines: sources, receptors, effects, and inducers. Clin. Microbiol. Rev. 10:742-80
15. Bone RC. 1996. Sir Isaac Newton, sepsis, SIRS and CARS. Crit. Care Med. 24:1125-28
16. Volk HD, Reinke P, Docke WD. 2000. Clinical aspects: from systemic inflammation to "immunoparalysis." Chem. Immunol. 74:162-77
17. Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138-50
18. Thijs LG, deBoer JP, de Groot MCM, et al. 1993. Coagulation disorders in septic shock. Intensive Care Med. 19(Suppl. 1):S8-15
19. Levi M, ten Cate H, van der Poll T, et al. 1993. Pathogenesis of disseminated intravascular coagulopathy in sepsis. JAMA 270:975-79
20. Aird WC. 2001. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit. Care Med. 29(Suppl. 7):28-35
21. Opal SM. 2003. Immune dysregulation and coagulation. In Sepsis: Pathophysiologic Insights and Current Management, ed. MM Levy, JL Vincent, 1:17-23. Des Plaines, IL: Soc. Crit. Care Med. 137 pp.
22. Broze GJ Jr. 1995. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul. Fibrinolysis 6(Suppl. 1):S7-13
23. Creasey AA. 2000. New potential therapeutic modalities: tissue factor pathway inhibitor. Sepsis 3:173-82
24. Wesselschmidt R, Likert K, Huang Z, et al. 1993. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul. Fibrinolysis 4:713-20
25. Levi M, van der Poll T, de Jonge E, et al. 1993. Relative insufficiency of the fibrinolytic system in disseminated intravascular coagulation. Sepsis 3:119-24
26. Hesselvik JF, Blomback M, Brodin B, et al. 1989. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit. Care Med. 17:724-33
27. van Hinsbergh VW, Kooistra T, van den Berg EA, et al. 1988. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72:1467-73
28. Paramo JA, Fernandez DF, Rocha E. 1988. Plasminogen activator inhibitor activity in bacterial infection. Thromb. Haemost. 59:451-54
29. Lorente JA, Garcia-Frade LJ, Landin L, et al. 1993. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536-42
30. Opal SM, Thijs LG. 1999. New potential therapeutic modalities: antithrombin III. Sepsis 3:153-59
31. Mammen EF. 1995. Clinical relevance of antithrombin deficiencies. Semin. Hematol 4(Suppl. 2):2-6
32. Mesters RW, Mannucci PW, Coppola R, et al. 1996. Factor VII and antithrombin III activity during sepsis and septic shock in neutropenic patients. Blood 96:2302-10
33. Eisele B, Lamy M, Thijs LG, et al. 1998. Anti-thrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized-placebo-controlled, double blind trials with antithrombin III in severe sepsis. Intensive Care Med. 24:663-72
34. Warren BL, Eid A, Singer P, et al. 2001. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-78
35. Esmon CT, Taylor FB Jr, Snow TR. 1991. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb. Haemost. 66:160-65
36. Bernard GR, Vincent JL, Laterre PF, et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709
37. Yan SB, Heiterbrand JD, Hartman DL, et al. 2001. Low levels of protein C are associated with poor outcomes in severe sepsis. Chest 120:915-22
38. Ely EW, Laterre PF, Angus DC, et al. for the PROWESS Investigators. 2003. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit. Care Med. 31:12-19
39. Bernard GR. 2003. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit. Care Med. 31(Suppl.):S85-93
40. Bernard GR, Macias WL, Joyce DE, et al. 2003. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care. 7:155-63
41. Dolovich LR, Ginsberg JS, Douketis JD, et al. 2000. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch. Intern. Med. 160:181-88
42. Siegel JP. 2002. Assessing the use of activated protein C in the treatment of severe sepsis. N. Engl. J. Med. 347:1030-34
43. Warren HS, Suffredini AF, Eichacker PQ, et al. 2002. Risks and benefits of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347:1027-30
44. Ely EW, Bernard GR, Vincent JL. 2002. Activated protein C for severe sepsis. N. Engl. J. Med. 347:1035-36
45. Knaus WA, Draper EA, Wagner DP, et al. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-29
46. Vincent JL, Sundin DP, Trzaskoma BL, et al. 2003. Change in first day vasopressor use is predictive of outcome in severe sepsis, regardless of steroid use. Crit. Care Med. 12(Suppl.):A116 (Abstr.)
47. Levy MM, Macias WL, Russell JA, et al. 2003. Failure to improve during first day of therapy is predictive of 28-day mortality in severe sepsis. Chest 124(Suppl.):120S (Abstr.)
48. Wheeler AP, Steingrub J, Linde-Zwirble W, et al. 2003. Prompt administration of drotrecogin alfa (activated) is associated with improved survival. Crit. Care Med. 12(Suppl.):A120 (Abstr.)
49. Schmidt G, Bates B, McCollam JS, et al. 2003. Clinical use of drotrecogin alfa (activated): patients treated in MERCURY differ from those in PROWES S. Crit. Care Med. 12(Suppl.):A116 (Abstr.)
50. Wheeler AP. 2004. Baseline characteristics and survival of adult severe sepsis patients treated with DA (activated) in a global, single arm, open label trial. Presented at Chest 2003, Am Coll. Chest Physicians (ACCP), Orland, FL. CD Prod. Code #4890
51. Vincent JL, Levy MM, Macias WL, et al. 2003. Early intervention with drotrecogin alfa (activated) improves survival benefit. Crit. Care Med. 12(Suppl.):A123 (Abstr.)
52. Bennett EL, Finland M, Hamborger M, et al. 1963. The effectiveness of hydrocortisone in the management of severe infection. JAMA 183:462-65
53. Bone RC, Fisher CJJ, Clemmer TP, et al. 1987. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317:653-58
54. Veterans Administration Systemic Sepsis Cooperative Study Group. 1987. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N. Engl. J. Med. 659-65
55. Luce JM, Montgomery AB, Marks JD, et al. 1988. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am. Rev. Resp. Dis. 138:62-68
56. Lefering R, Neugebauer EA. 1995. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit. Care Med. 23:1294-303
57. Cronin L, Cook DJ, Carlet J, et al. 1995. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. 23:1430-39
58. Annane D, Sebille V, Troche G, et al. 2000. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283:1038-45
59. Sharshar T, Blanchard A, Paillard M, et al. 2003. Circulating vasopressin levels in septic shock. Crit. Care Med. 31:1752-58
60. Annane D, Sebille V, Charpentier C, et al. 2002. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-71
61. Bollaert PE, Charpentier C, Levy B, et al. 1998. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit. Care Med. 26:645-50
62. Briegel J, Forst H, Haller M, et al. 1999. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med. 27:723-32
63. Matot I, Sprung CL. 1998. Corticosteroids in septic shock: resurrection of the last rites. Crit. Care Med. 26:627-30
64. Marik PE, Zaloga GP. 2003. Adrenal insufficiency during septic shock. Crit. Care Med. 31:141-15
65. Annane D, Briegel J, Keh D, et al. 2003. Clinical equipoise remains for issues of adrenocorticotropic hormone adminstration, cortisol testing, and therapeutic use of hydrocortisone. Crit. Care Med. 31:2250-51
66. Cooper MS, Stewart PM. 2003. Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. 348:727-34
67. Bloomfield R, MacMillan M, Noble DW. 2003. Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. 348:2158
68. Cortez A, Zito J, Lucas C. 1977. Mechanism of inappropriate polyuria in septic patients. Arch. Surg. 172:471-76
69. Rivers E, Nguyen B, Havstad S, et al. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345:1368-77
70. Gattinoni L, Brazzi L, Pelosi P, et al. 1995. A trial of goal-oriented hemodynamic therapy in critically ill patients. N. Engl. J. Med. 333:1025-32
71. Hayes MA, Timmins AC, Yau EHS, et al. 1994. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N. Engl. J. Med. 330:1717-22
72. Want L, Brown J, Varki A, et al. 2002. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J. Clin. Invest. 110:127-36
73. Tyrell DJ, Home AP, Holme KR, et al. 1999. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharm. 46:151-208
74. Davidson BL, Geerts WH, Lensing AWA. 2002. Low-dose heparin for severe sepsis. N. Engl. J. Med. 347:1036-37
75. Langer M, Riccardi F, Piovella F, et al. 2002. Use of anticoagulants in patients with sepsis. JAMA 287:448-19
76. Abraham E, Reinhart K, Opal S, et al. 2003. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-47
77. Wang H, Yang H, Tracey KJ. 2004. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 255:320-31
78. Wang H, Bloom O, Zhang M, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-51
79. Rendon-Mitchell B, Ochani M, Li J, et al. 2003. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170:3890-97
80. Scaffidi P, Misteli T, Bianchi ME. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-95
81. Yang H, Ochani M, Li J, et al. 2004. Reversing established sepsis with antagonists of endogenous HMGB1. Proc. Natl. Acad. Sci. USA. 101:296-301
82. Wang H, Yang H, Czura CJ, et al. 2001. HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Resp. Crit. Care Med. 164:1768-73
83. Abraham E, Arcaroli J, Carmody A, et al. 2000. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165:2950-54
84. Riedemann NC, Guo RF, Ward PA. 2003. Novel strategies for the treatment of sepsis. Nat. Med. 9:517-24
85. Ulloa L, Ochani M, Yang H, et al. 2002. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99:1235156
86. Ziegler EJ, McCutchan JA, Fierer J, et al. 1982. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1225-30
87. Greenman RL, Schein RMH, Martin MA, et al. 1991. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-102
88. Bone RC, Balk RA, Fein AM, et al. 1995. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit. Care Med. 23:994-1006
89. Angus DC, Birmingham MC, Balk RA, et al., for the E5 Study Investigators. 2000. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. JAMA 283:1723-30
90. Zeigler EJ, Fisher CJ Jr, Sprung CL, et al. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324:429-36
91. McCloskey RV, Straube RC, Sanders C, et al., for the CHESS Trial Study Group. 1994. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 121:1-5
92. 21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 356:961-67
93. Schedel I, Dreikhausen U, Nentwig B, et al. 1991. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit. Care Med. 19:1104-13
94. Bernard GR, Wheeler AP, Russell JA, et al., for the Ibuprofen in Sepsis Study Group. 1997. The effects of ibuprofen on the physiology and survival of patients with sepsis. N. Engl. J. Med. 336:912-18
95. Vincent JL, Brase R, Santman F, et al. 2001. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. 27:1578-83
96. Yu M, Tomasa G. 1993. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit. Care Med. 21:1635-12
97. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. 1994. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit. Care Med. 22:1720-28
98. Dhainaut JF, Tenaillon A, Hemmer M, et al., for the BN 52021 Sepsis Investigator Group. 1998. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 26:1963-71
99. Vincent JL, Spapen H, Bakker J, et al. 2000. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit. Care Med. 28:638-12
100. Opal S, Laterre PF, Abraham E, et al. and the Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis (COMPASS) Investigators. 2004. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. 32:332-11
101. Abraham E, Anzueto A, Gutierrez G, et al., for the NORASEPT II Study Group. 1998. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 351:929-33
102. Panacek EA, Marshall J, Fischkoff S, et al. 2000. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: results of the MONARCS trial. Chest 118:888
103. Fisher CJ Jr, Agosti JM, Opal SM, et al., for the Soluble TNF Receptor Sepsis Study Group. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N. Engl. J. Med. 334:1697-702
104. Abraham E, Glauser MP, Butler T, et al. 1997. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277:1531-38
105. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. 1994. Recombinant human interleukin l receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836-43
106. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. 1997. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 25:1115-24
107. Staubach KH, Schroder J, Stuber F, et al. 1998. Effect of pentoxifylline in severe sepsis. Results of a randomized, double-blind, placebo-controlled study. Arch. Surg. 133:94-100
108. Spies CD, Reinhart K, Witt I, et al. 1994. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit. Care Med. 22:1738-46
109. Peake SL, Moran JL, Leppard PI. 1996. N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Crit. Care Med. 24:1302-10
110. Angstwurm MW, Schottdorf J, Schopohl J, Gaertner R. 1999. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Crit. Care Med. 27:1807-13
111. Fein A, Bernard GR, Criner GJ, et al. 1997. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): results of a randomized, double-blind, placebo-controlled trial. JAMA 277:482-87
112. G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (Study No. 144-002). Crit. Care Med. 32:1-12
113. Lopez A, Lorente JA, Steingrub J, et al. 2004. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32:21-30
114. Petros A, Bennett D, Vallance P. 1991. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557-58
115. Preiser JC, Lejeune P, Roman A, et al. 1995. Methylene blue administration in septic shock: a clinical trial. Crit. Care Med. 23:259-64
116. Memis D, Karamanlioglu B, Yuksel M, et al. 2002. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesthesia Intensive Care 30:755-62
117. Nelson S, Heyder AM, Stone J, et al., for the Multilobar Pneumonia Study Group. 2000. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J. Infect. Dis. 182:970-73
118. Presneill JJ, Harris T, Stewart AG, et al. 2002. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Resp. Crit. Care Med. 166:138-13
119. Hoffman JN, Hartl WH, Deppisch, et al. 1996. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylotoxins and cytokines in human sepsis. Intensive Care Med. 22:1360-67
120. Heering P, Morgera S, Schmitz FJ, et al. 1997. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous veno-venous hemofiltration. Intensive Care Med. 23:288-96
121. Bower RH, Cerra FB, Bershadsky B, et al. 1995. Early enteral administration of a formula (Impact®) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit. Care Med. 23:436-49
122. Galban C, Montejo JC, Mesejo A, et al. 2000. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit. Care Med. 28:643-48